Terms: = Ovarian cancer AND CEBPA, CEBP, 1050, C/EBP-alpha, P49715 AND Treatment
14 results:
1. De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients.
Gu Y; Zheng H; Mo S; Guo T; Chen L; Yang J; Xiang Y
BMC Womens Health; 2023 Mar; 23(1):141. PubMed ID: 36978050
[TBL] [Abstract] [Full Text] [Related]
2. Graphene Oxide Enhances Biogenesis and Release of Exosomes in Human ovarian cancer Cells.
Gurunathan S; Kim JH
Int J Nanomedicine; 2022; 17():5697-5731. PubMed ID: 36466784
[TBL] [Abstract] [Full Text] [Related]
3. Knockdown of ENTPD5 inhibits tumor metastasis and growth via regulating the GRP78/p-eIF-2α/CHOP pathway in serous ovarian cancer.
Chen X; Zha Z; Wang Y; Chen Y; Pang M; Huang L; Chen Y
J Ovarian Res; 2022 Jun; 15(1):69. PubMed ID: 35668504
[TBL] [Abstract] [Full Text] [Related]
4. CCAAT enhancer binding protein α suppresses proliferation, metastasis, and epithelial-mesenchymal transition of ovarian cancer cells via suppressing the Wnt/β-catenin signaling.
Zhang LM; Li M; Tian CC; Wang TT; Mi SF
Neoplasma; 2021 May; 68(3):602-612. PubMed ID: 33780265
[TBL] [Abstract] [Full Text] [Related]
5. Incidence of occult malignancies identified during hysterectomies performed for benign indications.
Topdagi Yilmaz EP; Cimilli Senocak GN; Topdagi YE; Aynaoglu Yildiz G; Kumtepe Y
J Gynecol Obstet Hum Reprod; 2020 Mar; 49(3):101620. PubMed ID: 31449888
[TBL] [Abstract] [Full Text] [Related]
6. A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.
Reiss KA; Herman JM; Armstrong D; Zahurak M; Fyles A; Brade A; Milosevic M; Dawson LA; Scardina A; Fischer P; Hacker-Prietz A; Kinders RJ; Wang L; Chen A; Temkin S; Horiba N; Stayner LA; Siu LL; Azad NS
Gynecol Oncol; 2017 Mar; 144(3):486-490. PubMed ID: 28109627
[TBL] [Abstract] [Full Text] [Related]
7. Myricetin induces apoptosis via endoplasmic reticulum stress and DNA double-strand breaks in human ovarian cancer cells.
Xu Y; Xie Q; Wu S; Yi D; Yu Y; Liu S; Li S; Li Z
Mol Med Rep; 2016 Mar; 13(3):2094-100. PubMed ID: 26782830
[TBL] [Abstract] [Full Text] [Related]
8. Effect of Quercetin on Cell Cycle and Cyclin Expression in ovarian Carcinoma and Osteosarcoma Cell Lines.
Catanzaro D; Ragazzi E; Vianello C; Caparrotta L; Montopoli M
Nat Prod Commun; 2015 Aug; 10(8):1365-8. PubMed ID: 26434118
[TBL] [Abstract] [Full Text] [Related]
9. Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.
Singh PP; Joshi S; Russell PJ; Nair S; Khatri A
BMC Cancer; 2011 Aug; 11():368. PubMed ID: 21861932
[TBL] [Abstract] [Full Text] [Related]
10. Synthetic isothiocyanate indole-3-ethyl isothiocyanate (homoITC) enhances sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to cisplatin.
Stehlik P; Paulikova H; Hunakova L
Neoplasma; 2010; 57(5):473-81. PubMed ID: 20568902
[TBL] [Abstract] [Full Text] [Related]
11. Influence of tamoxifen on cisplatin-sensitivity and estrogen receptors expression in ovarian carcinoma cell lines.
Nowak-Markwitz E; Maciejczyk A; Pudełko M; Tserenchunt G; Balázs G; Spaczyński M; Zabel M; Dietel M; Lage H; Surowiak P
Ginekol Pol; 2010 Mar; 81(3):183-7. PubMed ID: 20486538
[TBL] [Abstract] [Full Text] [Related]
12. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
[TBL] [Abstract] [Full Text] [Related]
13. Taxanes in ovarian cancer treatment.
Seetalarom K; Kudelka AP; Verschraegen CF; Kavanagh JJ
Curr Opin Obstet Gynecol; 1997 Feb; 9(1):14-20. PubMed ID: 9090476
[TBL] [Abstract] [Full Text] [Related]
14. The response of uterine fibroids to GnRH-agonist treatment can be predicted in most cases after one month.
Hackenberg R; Gesenhues T; Deichert U; Duda V; Schmidt-Rhode P; Schulz KD
Eur J Obstet Gynecol Reprod Biol; 1992 Jul; 45(2):125-9. PubMed ID: 1386817
[TBL] [Abstract] [Full Text] [Related]
